(2R)-1-[({2-[(2R)-4-カルバモイル-N-[(1S)-1-カルバモイルエチル]-2-[(2S)-2-[(2R)-2-{[(2R,3R,4R,5S,6R)-3-アセトアミド-2,5-ジヒドロキシ-6-(ヒドロキシメチル)オキサン-4-イル]オキシ}プロパンアミド]プロパンアミド]ブタンアミド]エトキシ}(ソジオオキシ)ホスホリル)オキシ]-3-(ヘキサデカノイルオキシ)プロパン-2-イル ヘキサデカノアート 化学特性,用途語,生産方法
使用
Osteosarcoma.
作用機序
Being a
phospholipid, mifamurtide accumulates in the lipid bilayer of the liposomes upon infusion. After
application of the liposomal infusion, the drug is cleared from the plasma within minutes. However, it is
concentrated in lung, liver, spleen, nasopharynx and thyroid, and the terminal half-life is 18 hours,
which is longer than the natural substance.
臨床応用
Mifamurtide is an anticancer agent for the treatment of osteosarcoma, the most common primary
malignancy of bone tissue mainly affecting children and adolescents. The drug was invented by
Ciba-Geigy (now Novartis) in the early 1980s and the agent was subsequently licensed to Jenner
Biotherapies in the 1990s. IDM Pharma bought the rights to the drug from Jenner in April 2003.In March 2009, mifamurtide was approved in the 27 European Union member states plus Iceland,
Liechtenstein and Norway via a centralized marketing authorization. After the approval, IDM Pharma
was acquired by Takeda, which began launching mifamurtide, as Mepact ®, in February 2010.
Mifamurtide, a fully synthetic lipophilic derivative of muramyl dipeptide (MDP), is muramyl tripeptide
phosphatidylethanolamine (MTP-PE), which is formulated as a liposomal infusion.
(2R)-1-[({2-[(2R)-4-カルバモイル-N-[(1S)-1-カルバモイルエチル]-2-[(2S)-2-[(2R)-2-{[(2R,3R,4R,5S,6R)-3-アセトアミド-2,5-ジヒドロキシ-6-(ヒドロキシメチル)オキサン-4-イル]オキシ}プロパンアミド]プロパンアミド]ブタンアミド]エトキシ}(ソジオオキシ)ホスホリル)オキシ]-3-(ヘキサデカノイルオキシ)プロパン-2-イル ヘキサデカノアート 上流と下流の製品情報
原材料
準備製品